European Society of Cardiology
Heart Failure 2023
This guideline holds 128 pages.
Summary
The 2023 ESC Heart Failure Guidelines update the evidence base for four-pillar therapy (ARNI, beta-blocker, MRA, SGLT2-i) and extend recommendations to HFpEF with empagliflozin and dapagliflozin. Simultaneous low-dose initiation is now preferred over sequential up-titration.
How the evidence was graded
Grading system
Class I
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- European Society of Cardiology
- Published
- 2023
- Version
- 2023 Update
- Region
- EU
- Language
- English
- Grading system
- Class I
Keywords
- Heart Failure
- HFrEF
- HFpEF
- SGLT2i
- ARNI
- Four-pillar therapy
